Research Paper Volume 15, Issue 13 pp 6503—6525

Figure 2. Enhanced sorafenib resistance and suppressed sorafenib-mediated ferroptosis in HCC cells with Galectin-1 overexpression. (A, B) Analysis of Galectin-1 expression in Huh-7, Huh-7/SR, vector control (Huh-7/Ctrl), and Galectin-1 overexpressing Huh-7 (Huh-7/Gal-1) cells through Western blotting and qRT-PCR. (C) Cell viability of HCC cells treated with various doses of sorafenib was examined using the MTT assay. (D) Analysis of cancer stem cell marker (Oct-4, Nanog, SOX-2, and KLF4) expression through qRT-PCR and Western blotting. (E) Detection of Galectin-1, glutathione peroxidase 4 (GPX4), and FTH-1 expression in Galectin-1-overexpressing cells, cells treated with sorafenib (10 μM) for 48 h, and cells not treated with sorafenib. (F) Lipid peroxidation detected using the malondialdehyde (MDA) assay. Data are presented as means ± standard deviations. *P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t test).